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ARTICLE OPEN
TOMM40 ‘523’ poly-T repeat length is a determinant of
longitudinal cognitive decline in Parkinson’s disease
Megan C. Bakeberg 1,2✉, Anastazja M. Gorecki1,3, Abigail L. Pfaff 1,4, Madison E. Hoes 1, Sulev Kõks 1,4, P. Anthony Akkari1,2,4,
Frank L. Mastaglia1,2,4 and Ryan S. Anderton 1,2,5
The translocase of outer mitochondrial membrane 40 (TOMM40) ‘523’ polymorphism has previously been associated with age of
Alzheimer’s disease onset and cognitive functioning in non-pathological ageing, but has not been explored as a candidate risk
marker for cognitive decline in Parkinson’s disease (PD). Therefore, this longitudinal study investigated the role of the ‘523’ variant in
cognitive decline in a patient cohort from the Parkinson’s Progression Markers Initiative. As such, a group of 368 people with PD
were assessed annually for cognitive performance using multiple neuropsychological protocols, and were genotyped for the
TOMM40 ‘523’ variant using whole-genome sequencing data. Covariate-adjusted generalised linear mixed models were utilised to
examine the relationship between TOMM40 ‘523’ allele lengths and cognitive scores, while taking into account the APOE ε
genotype. Cognitive scores declined over the 5-year study period and were lower in males than in females. When accounting for
APOE ε4, the TOMM40 ‘523’ variant was not robustly associated with overall cognitive performance. However, in APOE ε3/ε3 carriers,
who accounted for ~60% of the whole cohort, carriage of shorter ‘523’ alleles was associated with more severe cognitive decline in
both sexes, while carriage of the longer alleles in females were associated with better preservation of global cognition and a
number of cognitive sub-domains, and with a delay in progression to dementia. The findings indicate that when taken in
conjunction with the APOE genotype, TOMM40 ‘523’ allele length is a significant independent determinant and marker for the
trajectory of cognitive decline and risk of dementia in PD.
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INTRODUCTION
Cognitive impairment is a notable symptom of Parkinson’s disease
(PD), not only because of its impact on patient-perceived quality
of life, but also because significant dysfunction will affect a high
proportion of people with PD (PwP) as the disease progresses1,2.
Past research has reported a marked degree of clinical hetero-
geneity and different patterns of brain pathology have been
identified as the underlying basis for cognitive decline in PD3–5,
suggestive of a variable underlying pathophysiology and a
complex interaction between different risk factors, including
genetic variability. Candidate genes may account for a portion
of susceptibility to cognitive impairment in PwP, risk of Parkinson’s
disease dementia (PDD), and for the pattern of decline within
certain cognitive domains and rate of decline6–8.
Prior candidate genetic studies and genome-wide association
studies have been central in identifying genetic factors that
contribute to the development of cognitive dysfunction in PD, in
particular the significant role of Apolipoprotein E Epsilon 4 (APOE
ε4) in modulating risk of cognitive decline9–11. However,
alternative approaches, including analysis of structural variants12
and variation within noncoding regions of the genome13,14 may
also help to elucidate complex phenotypic heterogeneity15. One
structural variant of note is the ‘translocase of outer mitochondrial
membrane 40’ (TOMM40) polymorphic T-tract length (rs10524523,
‘523’); an intronic variant known to improve precision when
estimating the age of onset of Alzheimer’s disease (AD) in APOE ε3
carriers and to be associated with changes in cognition in non-
pathological ageing16–22. While the functional effects of
polymorphism at the ‘523’ locus remain largely unknown, a
reduction in the TOMM40 protein due to the decreased TOMM40
expression is known to be associated with α-synuclein accumula-
tion and a number of other effects, including increased reactive
oxygen species formation, oxidative damage, reduced mitochon-
drial integrity and neuroinflammation23–27. In view of the
purported functional impact of allelic variation at the ‘523’ locus,
coupled with the shared clinical, pathological and molecular
features of AD and PD28–30, polymorphism at this site is therefore
a plausible candidate to modulate the development and
progression of cognitive impairment in PD. Though, it is important
to note that consideration of the effect of APOEmust be taken into
account, as previously reported16.
Our group, along with others, have previously demonstrated
that polymorphism at the TOMM40 ‘523’ locus is not a determinant
of PD risk, although it may be a modifier of the age of symptom
onset31–33. However, studies examining the possible role of ‘523’
alleles in modulating cognitive decline in PD are fundamentally
lacking, with only a single cross-sectional study reporting a lack of
association with dementia in a mixed PD and diffuse Lewy body
disease (DLB) cohort34. Furthermore, with sexual dimorphism
being an increasingly reported phenomenon in the context of
both cognition35–37, as well as in the cognitive status of people
with PD38–40, it is imperative to consider such factors. As such, the
primary objective of the present study was to examine the role of
TOMM40 ‘523’ alleles as determinants of the severity and
trajectory of cognitive decline in a large, well-documented
Caucasian PD cohort, and to determine whether the alleles are
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associated with differential effects on specific cognitive domains,
when taking patient sex into account.
RESULTS
Baseline demographic and cognitive performance data
Baseline and longitudinal clinical and demographic information
and cognitive scores for the 368 participants are presented in
Supplementary Tables 2 and 3. At baseline, the majority of
participants were males (65.5%), had an average age of PD
symptom onset of 59.85 (±9.73) years, with a disease duration of
6.76 (±6.65) years, a mean age at the time of assessment of 61.79
(±9.56) years, and a mean education duration of 15.55 (±2.94)
years. Cognitive assessment scores at baseline were Montreal
Cognitive Assessment (MoCA) 27.22 (±2.24) points, Hopkins Verbal
Learning Test-Revised (HVLT) 24.46 (±4.94) points, Benton Judge-
ment of Line Orientation (BJLO) 12.85 (±2.07) points, Semantic
Fluency test—COMbined (SFCOM) 48.87 (±11.76) points,
Letter–Number Sequencing (LNS) 10.71 (±2.62) points and Symbol
Digit Modalities Test (SDMT) 41.08 (±9.53) points. Within this
group, repeated measures analyses revealed significant decline of
the MoCA (p= 0.004), LNS (p= 0.011) and SDMT (p= 0.044)
scores over the study period, while HVLT (p= 0.598), BJLO (p=
0.710) and SFCOM (p= 0.499) scores were not altered significantly
(Supplementary Table 4).
TOMM40 ‘523’ alleles and longitudinal cognitive performance
in whole cohort
As aforementioned, allelic and genotypic distributions of
TOMM40 ‘523’ are presented in Supplementary Table 1, with
45.2% of the 368 participants possessing the ‘523’ S allele, 10.7%
the L allele and 44% carrying the VL allele.
Subsequently, in adjusted generalised linear mixed models
(GLMMs), carriage of S alleles was associated with a significantly
greater decline in the MoCA score over the study period (p=
0.009; Bonferroni corrected p= 0.036), and decline in HVLT
(p= 0.017), and SFCOM scores (p= 0.001; Bonferroni corrected
p= 0.004; Table 1), though the decline in HVLT did not remain
statistically significant after Bonferroni correction. Conversely,
carriage of L alleles was associated with superior scoring in the
BJLO and LNS tests over the study period (p < 0.001 and p < 0.001,
respectively; Bonferroni corrected p= 0.004 and p= 0.004,
respectively). In unadjusted linear models, S and VL alleles were
associated with better performance in the LNS (p= 0.015) and
SDMT tests (p= 0.012), respectively, but these associations were
not confirmed after adjusted for covariates and multiple
comparison correction (Table 1).
TOMM40 ‘523’ alleles and cognitive performance in APOE ε3/
ε3 carriers
As previous literature has indicated that the predictive value of
TOMM40 ‘523’ in late-onset AD primarily applies to carriers of APOE
ε3, analyses were conducted again within the dominant sub-
group of APOE ε3/ε3 carriers (n= 205). In this group, unadjusted
linear models also demonstrated that presence of the S alleles was
associated with more severe global cognitive decline (p < 0.001;
Bonferroni corrected p= 0.004), as measured by the MoCA, and
with more severe decline in HVLT (p= 0.044), SFCOM (p= 0.009;
Bonferroni corrected p= 0.036) and SDMT (p= 0.001; Bonferroni
corrected p= 0.004) scores over time (Table 2), though decline in
HLVT did not remain statistically significant after Bonferroni
correction. These associations were confirmed in covariate-
adjusted models: MoCA (p < 0.001), SFCOM (p= 0.03) and SDMT
(p= 0.022; Table 2).
In contrast, carriage of longer ‘523’ alleles were associated with
preservation of cognitive performance in a number of domains.
Unadjusted modelling disclosed a positive association between VL
alleles and HVLT (p < 0.001), LNS (p= 0.006) and SDMT (p < 0.001)
scores over time (Table 2). After allowing for covariates, only the
association between VL alleles and better performance in the
SDMT test remained significant (p= 0.005; Bonferroni corrected
p= 0.020).
Sex-specific effects of TOMM40 ‘523’ alleles on longitudinal
cognitive performance in APOE ε3/ε3 carriers
As previous literature has indicated that cognitive ability and
cognitive decline significantly differ between males and females
with PD40, analyses were conducted again considering the sexes
as separate groups. The results are summarised in Table 3 and in
Supplementary Tables 5 and 6. While in males, unadjusted GLMMs
revealed a number of significant associations between ‘523’ alleles
and cognitive function, only the association between carriage of S
alleles and more severe decline in the MoCA remained significant
after adjusted for covariates (p= 0.011; Table 3).
Notably, in females a number of associations were apparent
between carriage of longer ‘523’ alleles and cognitive ability over
time. Unadjusted models revealed significant associations
between L alleles and worse decline in the HVLT (p= 0.033)
assessment (Supplementary Table 6), whereas carriage of VL
alleles was associated with significantly better performance over
time with the MoCA (p= 0.024), the BJLO (p= 0.039), SFCOM (p=
0.004) and LNS (p= 0.045) assessments (Supplementary Table 6).
Multivariable GLMMs confirmed that carriage of S alleles was
associated with significantly poorer performance in the MoCA
over time (p= 0.006; Table 3; Bonferroni corrected p= 0.024).
Finally, carriers of VL alleles had significantly better longitudinal
cognitive performance with the MoCA (p= 0.002; Bonferroni
corrected p= 0.008), BJLO (p= 0.050), SFCOM (p= 0.001; Bonfer-
roni corrected p= 0.004), LNS (p= 0.024) and SDMT (p= 0.020)
assessments, though BJLO, LNS and SDMT did not remain
significant after correction for multiple comparisons.
Effects of TOMM40 ‘523’ alleles on progression to PDD
The full cohort was subsequently analysed to examine the effect
of ‘523’ alleles on progression to PDD. As most baseline cognitive
scores were found to differ significantly between males and
females (Supplementary Table 2), analyses were carried out with
and without stratification by sex.
Firstly, combined ‘523’ allele lengths were compared between
the group with PDD and the group without dementia (PD-ND;
Supplementary Table 7). When gender was combined, no
significant differences were observable between the PDD and
PD-ND groups (50.88 ± 14.01 and 52.01 ± 13.62, respectively).
When separated by sex, combined ‘523’ allele length did not
significantly differ in males with PDD vs PD-ND (51.66 ± 14.14 and
51.67 ± 13.82, respectively), whereas in females there was a
significant difference in combined allele length between females
with PDD (48.03 ± 13.29) and females with PD-ND (52.59 ± 13.22;
p= 0.004; Bonferroni corrected p= 0.016), pointing to a protective
effect of longer alleles in females only.
In subsequent survival analyses, taking PDD diagnosis as the
endpoint, no significant differences were exhibited between ‘523’
S, L or VL carrier status when the sex of the Parkinson’s
Progression Markers Initiative (PPMI) cohort was combined (p=
0.944, p= 0.271 and p= 0.549, respectively). Analyses were re-run
using Cox proportional hazard regression models, adjusting for
APOE ε4 carrier status, and no significant associations were noted
(S allele, p= 0.805; L allele, p= 0.192; VL allele, p= 0.759). After
separating by sex, no significant associations were observable
between ‘523’ allele carrier status in males, using the Kaplan–Meier
method (Fig. 1A, S allele, p= 0.634; Fig. 1B, L allele, p= 0.181; Fig.
1C, VL allele, p= 0.465) or Cox proportional hazard regression
models (S allele, p= 0.608; L allele, p= 0.889; VL allele, p= 0.856),
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which adjusted for APOE ε4 carrier status. In females, there were
no significant observable effects with carriage of the S or L alleles
using the Kaplan–Meier method, though there was a trend
towards more rapid progression to dementia in females with the S
allele (Fig. 1D, S allele, p= 0.135; Fig. 1E, L allele, p= 0.709). Cox
proportional hazard regression found no significant effect when
adjusting for APOE ε4 carrier status (S allele, p= 0.218; L allele, p=
0.924). Notably, a significantly faster progression to dementia was
apparent in females who did not carry VL alleles (Fig. 1F, VL allele,
p= 0.033). This association remained significant when using Cox
proportional hazard regression (p= 0.013) and after adjusting for
carriage of APOE ε4, confirming that VL alleles may be protective.
Following Bonferroni correction these associations were indicative
of a trend, though not statistically significant.
TOMM40 ‘523’ alleles and progression to PDD in APOE ε3/ε3
carriers
Based upon PDD diagnosis, combined ‘523’ allele lengths were
compared between PDD vs PD-ND groups. When gender was
combined, a significant difference was observed between PDD
and PD-ND (49.32 ± 14.42 and 51.33 ± 14.52, respectively; p=
0.036). When separated by sex, males with PDD and PD-ND
exhibited no significant differences in combined ‘523’ allele length
(49.28 ± 14.62 and 50.20 ± 14.95, respectively; p= 0.388). However,
a significant difference in combined allele length was seen in
females with PDD (49.42 ± 13.99) compared to females with PD-
ND (53.25 ± 13.57; p= 0.043). While this association did not
remain significant after Bonferroni correction (p= 0.172), it is
suggestive of a protective effect of longer alleles.
Survival analysis using the Kaplan–Meier method, taking PDD
diagnosis as the endpoints, showed no significant differences
between S, L or VL carrier status when the sex of the PPMI cohort
was combined (p= 0.396, p= 0.211 and p= 0.217, respectively).
Cox proportional hazard regression models adjusting for sex also
failed to show any significant associations (S allele, p= 0.485; L
allele, p= 0.097; VL allele, p= .390). When considering males and
females separately, and after excluding carriers of the L allele due
to low numbers, no significant associations were observable
between ‘523’ allele carrier status and progression to PDD in males
(S allele, p= 0.587; VL allele, p= 0.720). Though no significance
was seen in female carriage of the S allele (S allele, p= 0.618), a
trend towards more rapid progression was observed in females
lacking the VL allele (VL allele, p= 0.152).
DISCUSSION
Cognitive impairment and progression to PDD are significant
determinants of morbidity and quality of life in PD. The genetic
contribution to these non-motor aspects of PD is an area of great
importance. Within studies examining cognitive decline in non-
pathological ageing populations19–22 and in cohorts of individuals
with AD17,18, the mitochondrial variant TOMM40 ‘523’ has been
implicated with mixed results. By comparison, two studies have
found no association between the TOMM40 ‘523’ and PD risk32,33,
while a third group found that the L/VL ‘523’ genotype was over-
represented in Swedish PD patients when compared to controls31.
However, research into whether TOMM40 ‘523’ alleles play a role in
modulating cognitive impairment and rate of decline within PD is
profoundly scant, with only a single cross-sectional study of a
Table 1. Differential effects of TOMM40 ‘523’ alleles in predicting cognitive performance over time, using unadjusted and adjusted generalised linear
mixed models (n= 368).
Unadjusted Adjusted
Model Outcome Intercept β-CoE SE t Value pb Value Intercept β-CoE SE t value pc Value
MoCA 26.827 −0.098 0.144 −0.679 0.497 31.953 −0.376 0.144 −2.610 0.009
HVLT 24.367 −0.108 0.282 −0.384 0.701 33.208 −0.658 0.276 −2.380 0.017
S presenta BJLO 12.643 0.155 0.109 1.432 0.152 13.973 0.073 0.112 0.650 0.516
(n= 333) SFCOM 48.922 −0.172 0.619 −0.278 0.781 57.851 −1.892 0.592 −3.194 0.001
LNS 10.184 0.349 0.143 2.440 0.015 15.489 0.164 0.142 1.159 0.247
SDMT 40.498 −0.059 0.546 −0.108 0.914 63.680 −0.950 0.517 −1.837 0.066
MoCA 26.767 −0.052 0.157 −0.331 0.740 31.677 0.112 0.318 0.353 0.724
HVLT 24.287 0.012 0.306 0.039 0.969 33.053 0.535 0.614 0.872 0.384
L presenta BJLO 12.769 −0.071 0.118 −0.602 0.547 14.207 0.927 0.247 3.750 <0.001
(n= 79) SFCOM 48.697 0.458 0.673 0.681 0.496 61.144 2.122 1.315 1.614 0.107
LNS 10.373 0.275 0.156 1.765 0.078 15.575 1.126 0.312 3.607 <0.001
SDMT 40.476 −0.092 0.593 −0.155 0.877 65.906 1.024 1.145 0.894 0.372
MoCA 26.757 −0.001 0.141 −0.001 0.994 31.663 0.020 0.136 0.145 0.885
HVLT 23.985 0.443 0.274 1.615 0.106 32.746 0.371 0.261 1.422 0.155
VL presenta BJLO 12.816 −0.091 0.106 −0.856 0.391 14.315 −0.109 0.106 −1.033 0.302
(n= 116) SFCOM 48.665 0.193 0.602 0.321 0.748 61.107 0.080 0.559 0.144 0.886
LNS 10.437 −0.005 0.140 −0.039 0.969 15.626 −0.035 0.133 −0.263 0.793
SDMT 39.540 1.329 0.531 2.501 0.012 65.463 0.554 0.488 1.137 0.256
The numbers in bold are indicative of statistical significance.
S short, L long, VL very long, MoCa Montreal Cognitive Assessment, HVLT Hopkins Verbal Learning Test-Revised, BJLO Benton Judgement of Line Orientation,
SFCOM Semantic Fluency test—COMbined, LNS the Letter–Number Sequencing, SDMT Symbol Digit Modalities Test, β-CoE beta coefficient, SE standard error, p
statistical significance (p value).
aComparison category set to zero.
bp Value taken from GLMM without adjustment for covariates.
cp Value taken from GLMM adjusting for APOE ε4 status, as well as covariates identified in Supplementary Table 4, including years between assessments, age at
assessment, age at disease onset, disease duration, gender and years of education.
M.C. Bakeberg et al.
3
Published in partnership with the Parkinson’s Foundation npj Parkinson’s Disease (2021)    56 
mixed PD and DLB cohort reporting that TOMM40 ‘523’ is not
associated with risk of dementia34. To our knowledge, no previous
studies have explored the relationship between TOMM40 ‘523’
poly-T length variability and domain-specific cognitive decline or
progression to dementia in PD, or differential effects of
TOMM40 ‘523’ alleles on cognition in males and females. As such,
this is the first study to assess this relationship in a large, well-
documented PD cohort undergoing serial cognitive assessments
over a 5-year period. Our findings indicate that the TOMM40 ‘523’
polymorphism does play a part in modulating cognitive decline,
and suggest that alleles of ‘523’ have differential sex effects, with
shorter alleles being associated with greater global cognitive
decline in both males and females, whereas longer alleles have
both global and domain-specific protective effects in females
with PD.
In past literature, case–control analysis has found that while
TOMM40 ‘523’ does not modulate or influence the risk of
developing PD, it may affect the age at which symptoms
develop32,33. The findings of the present study provide evidence
that polymorphism in TOMM40 ‘523’ may also have significant
effects on cognitive decline and progression to PDD, independent
of the influence of APOE ε4. While our findings demonstrate an
effect of ‘523’ on cognitive measures over time, significant
differences were seen in the trajectory of cognitive decline and
progression to PDD in females. Specifically, survival analysis
showed a trend towards an association of S allele carriage with
faster progression to PDD, whereas carriage of VL alleles was
significantly protective in terms of progression to PDD in females,
but not males. Furthermore, combined ‘523’ allele length was
significantly shorter in females with PDD compared to those
without dementia (PD-ND group).
In view of the linkage disequilibrium which exists between
TOMM40 and APOE, in order to accurately assess the independent
contribution of ‘523’ allelic variation, APOE genotypes must be
taken into account16. Thus, further analysis examined the sub-
cohort of carriers of APOE ε3/ε3, which is the most common
genotype and accounted for ~60% of the present PD cohort. The
aforementioned associations in the whole cohort were reflected in
the assessment-specific analysis of the sub-cohort of APOE ε3/ε3
carriers, when adjusting for covariates. For instance, S allele
carriage was associated with greater decline in global cognitive
ability (MoCA), as well as language fluency (measured by SFCOM
assessment) and processing speed and attention (SDMT); while
possession of VL alleles was protective of processing speed and
attention. However, it is likely that these findings were also being
driven by gender, as a number of significant associations between
the ‘523’ variant and cognitive decline in females were not
apparent in males. In particular, within the female APOE ε3/ε3
group, ‘523’ S allele carriage was associated with a significantly
worse overall MoCA score, whereas VL alleles were significantly
protective in terms of overall cognition (MoCA score), as well as
visuospatial function, language fluency, and superior executive
function and working memory. Moreover, in the APOE ε3/ε3 sub-
cohort, no ‘523’ allele stratification was observable in males with
PD, whereas VL alleles appeared to be associated with slower
progression to PDD (though not statistically significant) in females.
It is possible that with a larger sample size of APOE ε3/ε3 genotype
carriers, this allele and sex association may be confirmed. Taken
together, these findings suggest that increasing TOMM40 ‘523’
allele length has a protective effect in terms of cognitive decline in
people with PD, and this effect is more noticeable in females.
Interestingly, a shorter TOMM40 allele length appeared to be a
risk factor for deterioration in cognitive performance over time in
this PPMI cohort. Such findings appear to be reflective of those
found in a smaller, cross-sectional study by Lindqvist and
colleagues34, though this group reported that both S and VL
alleles exhibited a trend towards being associated with dementia
in a mixed PDD and DLB cohort. Overall, such variable associations
between TOMM40 ‘523’ and aspects of cognition must be
interpreted with caution. Furthermore, it is important to consider
underlying differences between the two cohorts that might
explain variation in findings, such as the age at disease onset, as a
number of studies in the literature have suggested that an older
age of onset is more likely to be associated with cognitive
Table 2. Capacity of TOMM40 alleles in predicting cognitive performance over time, using unadjusted and adjusted generalised linear mixed models,
in the sub-group of APOE ε3/ε3 carriers within the PPMI cohort.
Unadjusted Adjusted
Model Outcome Intercept β-CoE SE t Value pb Value Intercept β-CoE SE t Value pc Value
MoCA 27.365 −0.710 0.198 −3.576 <0.001 31.108 −0.661 0.189 −3.506 <0.001
HVLT 25.092 −0.812 0.403 −2.015 0.044 31.227 −0.629 0.372 −1.692 0.091
S presenta BJLO 12.747 0.068 0.158 0.431 0.667 12.733 0.040 0.153 0.261 0.795
(n= 219) SFCOM 51.288 −2.200 0.835 −2.635 0.009 54.430 −1.665 0.792 −2.102 0.036
LNS 10.448 0.017 0.195 0.085 0.932 14.199 0.026 0.187 0.137 0.891
SDMT 43.064 −2.477 0.745 −3.324 0.001 58.218 −1.522 0.662 −2.300 0.022
MoCA 26.564 0.338 0.181 1.864 0.063 30.692 0.042 0.172 0.245 0.806
HVLT 23.527 1.286 0.365 3.524 <0.001 30.391 0.463 0.338 1.370 0.171
VL presenta BJLO 12.779 0.029 0.143 0.206 0.837 12.684 0.068 0.138 0.488 0.626
(n= 189) SFCOM 48.624 1.299 0.759 1.713 0.087 53.685 −0.136 0.719 −0.190 0.850
LNS 10.112 0.487 0.176 2.769 0.006 13.960 0.237 0.169 1.401 0.161
SDMT 38.848 3.158 0.674 4.687 <0.001 55.592 1.702 0.600 2.835 0.005
The numbers in bold are indicative of statistical significance.
S short, L long, VL very long, MoCa Montreal Cognitive Assessment, HVLT Hopkins Verbal Learning Test-Revised, BJLO Benton Judgement of Line Orientation,
SFCOM Semantic Fluency test—COMbined, LNS the Letter–Number Sequencing, SDMT Symbol Digit Modalities Test, β-CoE beta coefficient, SE standard error, p
statistical significance (p value).
aComparison category set to zero.
bp Value taken from GLMM without adjusting for covariates.
cp Value taken from GLMM adjusting for covariates identified in Supplementary Table 4, including years between assessments, age at assessment, age at
disease onset, disease duration, gender and years of education.
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impairment41–46. Although information on age of onset was not
provided in the Lindqvist paper34, their patient cohort appears to
have been older than the PPMI cohort, which was comprised of
recently diagnosed PwP with a mean age of onset of 59.9 years.
The strengths of the present study are that it examined this
relationship longitudinally in a large, homogeneous PD cohort,
while considering the effect of the APOE ε4 carrier status, as well
as the known variability of cognitive trajectory between males and
females40. As such, the findings here support the notion that the
TOMM40 ‘523’ poly-T repeat variants do play a role in modulating
cognitive decline in PwP, independently of the effects of APOE ε4.
As indicated by genetic studies, the role of mitochondrial
dysfunction in PD aetiology and pathogenesis is increasingly well-
recognised. A recent study consistently observed that TOMM40
protein deficits in brain samples from PwP correlated with a
higher number of mitochondrial DNA deletions, and with
enhanced oxidative stress, reduced ATP production and abnormal
complex I protein concentrations25. Furthermore, it has been
shown that TOMM40-facilitated importation of α-synuclein into
mitochondria inhibits mitochondrial complex I26, a common
source of mitochondrial dysfunction in PD. In addition to this,
TOMM40 is closely associated with the functioning of two familial
PD genes, Parkin and PINK1, where TOMM40 is required by the
PINK1 protein for mitochondrial localisation and Parkin recruit-
ment in mitophagy47. Clearly, this variant may play a pathophy-
siological role in the disease risk and progression of PD. This, when
combined with findings from studies that implicate the TOMM40
variant in AD, cognitive decline in the healthy ageing and in DLB,
is why such a variant is proposed as a region of interest in the
context of PD-related cognitive ability.
Certain limitations of the present study should be noted. Firstly,
as the PPMI cohort comprised only recently diagnosed PwP (with
a mean disease duration of ~7 years and a mean age at onset of
~60 years), the present findings need to be confirmed in broader,
more representative community-based PD cohorts. Moreover, as
the cohort we examined was purely Caucasian, further studies are
required to determine whether the reported allelic associations
are also present in other racial and ethnic groups. In addition,
given it has been suggested that using WGS for genotyping
TOMM40 ‘523’ may be less accurate than PCR-based techniques
for longer alleles48, further studies should compare allelic
associations using the two methods. Though the study was based
on the use of well-recognised and validated cognitive instruments,
future studies may benefit from utilising more comprehensive
cognitive assessment protocols or modern imaging technology.
Finally, despite being a comprehensive cohort, analyses of the L
allele presented with power issues and, in some analyses, had to
be excluded. Thus, future analyses using even larger comprehen-
sive cohorts are warranted.
Although the role of the TOMM40 ‘523’ poly-T repeat has been
well-explored in AD and healthy age-related cognitive decline,
there is a paucity of studies investigating whether it has a role in
cognitive decline in PD. The findings of the present longitudinal
study in a large PD cohort from the PPMI provide the first
evidence that the poly-T repeat length is a significant determinant
of cognitive decline, independent of APOE4, and that the effects
are sex-dependent. Thus, while short TOMM40 ‘523’ alleles were
associated with more severe cognitive decline in both sexes, in
females, longer alleles were associated with protective effects on
global cognition, as well as particular cognitive sub-domains,
including attention and processing speed, language fluency,
working memory. and executive and visuospatial functions, and
appeared to delay progression to PDD. Our findings highlight the
importance of the TOMM40 ‘523’ polymorphism in cognitive
decline in PD and suggest that further studies in other PD
populations would be worthwhile. When combined with sex and
APOE genotype, TOMM40 ‘523’ may be a viable prognostic marker,
and may assist in understanding the pathology underlying
cognitive decline in PD.
METHODS
Participant recruitment and clinical evaluation of PD
The study considered 423 de novo PwP from the PPMI study cohort, out of
which successful ‘523’ genotyping was carried out in 368 individuals (see
section “TOMM40 ‘523’ alleles and cognitive performance in APOE ε3/ε3
carriers”). Following this, as ‘523’ allele frequencies have been shown to be
ethnic-specific49 all individuals categorised as Black, Asian, Hispanic/Latino
or other were excluded to ensure a more homogenous Caucasian cohort.
Data were collected longitudinally from January 2011, with six 12 monthly
time points being considered (baseline, 1 year, 2 years, 3 years, 4 years and
5 years). All data pertaining to the PPMI cohort were obtained from the
PPMI database (available at http://www.ppmi-info.org/data) on 1st
November 2020. For up-to-date information on the study, visit http://
www.ppmi-info.org. Inclusion criteria and more specific details of the PPMI
study can be found in a previously published communication50.
Detailed demographic information was collected from all participants,
including age at symptom onset, age at current assessment, disease
duration and level of educational attainment. Anti-Parkinsonian
Table 3. Summary of differential associations of TOMM40 alleles with longitudinal cognitive measures in male and female APOE ε3/ε3 carriers in the
PPMI cohort.
S allelea (n= 219) VL allelea (n= 189)
Assessment Males Females Males Females
β-CoE pb Value β-CoE pb Value β-CoE pb Value β-CoE pb Value
MoCA −0.602 0.011 −0.905 0.006 −0.307 0.125 1.024 0.002
HVLT −0.743 0.128 −0.917 0.117 0.363 0.383 0.912 0.120
BJLO 0.100 0.576 0.195 0.476 −0.168 0.269 0.542 0.050
SFCOM −2.023 0.051 −1.958 0.123 −1.697 0.053 4.235 0.001
LNS −0.141 0.561 0.306 0.315 0.035 0.867 0.687 0.024
SDMT −1.409 0.099 −1.815 0.094 1.304 0.073 2.543 0.020
The numbers in bold are indicative of statistical significance.
S short, L long, VL very long, MoCa Montreal Cognitive Assessment, HVLT Hopkins Verbal Learning Test-Revised, BJLO Benton Judgement of Line Orientation,
SFCOM Semantic Fluency test—COMbined, LNS the Letter–Number Sequencing, SDMT Symbol Digit Modalities Test, β-CoE beta coefficient, SE standard error, p
statistical significance (p value).
aComparison category set to zero.
bp Value taken from GLMM adjusting for covariates identified in Supplementary Table 4, including years between assessments, age at assessment, age at
disease onset, disease duration and years of education.
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medication dosage was obtained from the PPMI database as a total
levodopa equivalent daily dose. All subjects were comprehensively
evaluated, with motor symptom severity being assessed using the
Movement Disorder Society-Unified Parkinson’s Disease Rating Scale)
Part III, and disease severity on the Hoehn and Yahr scale51. The research
involving human data was assessed and approved by The University of
Western Australia Human Research Ethics Committee (approval number:
RA/4/20/4293 and RA/4/20/4470). Written informed consent was
obtained from all participants, visit http://www.ppmi-info.org for more
information.
Cognitive testing
Clinical and cognitive information utilised was also obtained from the PPMI
database (available at http://www.ppmi-info.org/data). The neuropsycho-
logical assessments performed on PD subjects have been described
previously52. Briefly, the PPMI utilised (i) the MoCA as a measure of global
cognitive function (assessing working memory, visuospatial abilities,
attention, language, orientation and executive function; score range:
0–30 points); (ii) the HVLT which measures episodic verbal memory
(whereby 12 words are learned in triplicates and then a delayed recall is
assessed); (iii) the BJLO, which is a measure of visuospatial function
(whereby five practice items assessing spatial perception and orientation
Fig. 1 Possession of TOMM40 ‘523’ VL allele is significantly protective against progression to PDD. Kaplan–Meier curves showing the effect
of TOMM40 ‘523’ allele length on the proportion of male participants diagnosed with PDD (S allele, A; L allele, B; and VL allele, C), as well as in
females (D, E, F). PDD Parkinson’s disease dementia, S short, L long, VL very long.
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are followed by a testing period); (iv) the SFCOM to assess verbal fluency
(multiple verbal fluency tests, being vegetable, fruit and animal fluency, are
combined to assess verbal and lexical fluency); (v) the LNS test for
executive function and working memory (in this test verbal working
memory is tested by repeating a string of random letters and numbers to
the assessor in ascending and alphabetical order); and (vi) the SDMT to
assess processing speed and attention (this test uses geometric figures and
numbers in a matching task)53,54. More detailed information regarding the
cognitive assessments can be obtained at https://www.ppmi-info.org/
study-design/research-documents-and-sops/. Published norms were
applied for each of the various assessments55–59.
Finally, the diagnosis of PDD was made by the referring PPMI
investigators, based on criteria developed by the MDS;1,60,61 and including
information obtained from patients and family members, and cognitive
impairment as defined by impaired performance (>1.5 SD below the mean)
in at least two domains of one or more cognitive tests, together with
evidence of functional impairment in everyday life as a result of cognitive
dysfunction.
TOMM40 rs10524523 and APOE ε genotyping
Whole-genome sequencing data for the cohort of 423 cases were obtained
from the PPMI database (available at http://www.ppmi-info.org/data), in
order to genotype the rs10524523 (‘523’) risk allele in the PPMI cohort. As
previously described33, binary alignment map files were aligned to the
human reference genome GRCh38 using the Burrows-Wheeler transform
alignment algorithm, and were analysed using the Integrative Genomics
Viewer62, in order to calculate the length of the poly-T repeat, as previously
demonstrated48. Repeat lengths were called by four separate investigators,
and were checked for reproducibility. In samples where inter-rater
differences existed, a fifth independent experienced investigator was
conferred with, and when differences could not be reconciled that case
was excluded. As a result, an unequivocal ‘523’ genotype was successfully
determined in 368 of the 423 participants. Following this, individual poly-
Ts were grouped as follows using the convention established by Roses
et al.18: short (S, ≤19 Ts), long (L, 20–29 Ts) and very long (VL, ≥30 Ts). In
addition, allele lengths in each individual were combined to calculate a
total allele length. The APOE ε genotype was obtained from the PPMI
database (available at www.ppmi-info.org/data), which was determined by
the PPMI using TaqMan genotyping assays (Applied Biosystems Assay-On-
Demand part numbers C_3084793_20 and C_904973_10)63, and involved
the 7900HT Sequence Detection System (Applied Biosystems). Allelic and
genotypic distributions of TOMM40 ‘523’ and APOE variants in the cohort of
368 PwP are presented in Supplementary Table 1, and frequencies of
TOMM40 alleles relative to APOE allele carriage can be found online, as has
been previously reported33. Each distribution was compared to distribu-
tions of European cohorts on the Webstr database, as previously
reported33. Levene’s Test of Equality of Variances returned no significant
differences, and observable similarities were discernible in the ‘523’ allele
distribution of cohorts. Thus, the current cohort were considered reflective
of a population of European descent and within Hardy-Weinberg
equilibrium.
Statistical methods
The PPMI cohort was analysed using IBM-SPSS software (version 26, IBM
Corporation). A significant nominal p value < 0.05 was employed for all
statistical tests. Variables were described using mean and standard
deviation (SD), or frequency and percent (%), as appropriate. Normality
was assessed using the Shapiro-Wilk test, with subsequent clinical
characteristics analysed using independent samples T test, Mann–Whitney
U, Kruskal-Wallis or Chi-square, as appropriate.
Within longitudinal studies, trends of mean clinical assessments and
patient clinical characteristics were assessed over time using GLMMs.
Unadjusted GLMMs were used as univariate models to assess if clinical
characteristics were significantly associated with cognitive examination
scores over time. Variables identified as being statistically significant in
univariate models, as well as APOE ε4 status, were considered covariates
and were included in multivariable adjusted GLMMs. Variables included in
multivariable models as covariates included years between assessments,
age at assessment, age at disease onset, disease duration, gender, years of
education and APOE ε4 status (0, 1 or 2 copies). For determining the
presence of multicollinearity, the variance inflation factor (VIF) was
calculated for all independent variables. For all reported models, VIF
values were <2. Adjusted GLMMs were constructed to assess the impact of
‘523’ genotype on cognition over time, independently of other covariates.
As multiple comparisons were made in this exploratory study, we report
both unadjusted p values, covariate-adjusted p values and covariate
adjusted with Bonferroni corrected p values for each analysis. Bonferroni
corrected p values were calculated by multiplying the p value to reflect the
level of multiple hypotheses tested in this manuscript, being four levels.
Furthermore, Akaike information criterion was used to compare model fit,
where all multivariable models had lower values than unadjusted models,
indicating better model fit. Residual plots were examined for all models
and no violations were noted.
To evaluate the association between TOMM40 ‘523’ genotype and
progression to PDD, participants were stratified into PDD (dementia) or PD-
ND (no dementia) groups, and mean combined ‘523’ allele lengths were
compared between these groups and survival curves were estimated by
the Kaplan–Meier method. To compare the survival curves, the log-rank
test was applied, placing weight on longer survival periods64,65. In addition,
all distributions of ages at PDD onset were compared via Cox proportional
hazard regression models, while adjusting for APOE ε4 status. All
aforementioned statistical analyses were also carried out when separating
the cohort by sex, which is previously reported to be a significant factor in
cognitive impairment within PD40 and in the sub-group of APOE ε3/ε3
carriers16.
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